Literature DB >> 28112061

Inflammation and depression: a causal or coincidental link to the pathophysiology?

Brian E Leonard1.   

Abstract

This review summarises the evidence that chronic low grade inflammation triggers changes that contribute to the mental and physical ill health of patients with major depression. Inflammation, and the activation of the hypothalamic pituitary axis by stress, are normal components of the stress response but when stress is prolonged and the endocrine and immune system become chronic resulting in the activation of the peripheral macrophages, the central microglia and hypercortisolemia, the neuronal networks are damaged and become dysfunctional. The proinflammatory cytokines, in addition to activating the hypothalamic-pituitary-adrenal axis and thereby increasing cortisol synthesis, also activate the tryptophan-kynurenine pathway. This results in the synthesis of the neurotoxic N-methyl-d-aspartate (NMDA) glutamate agonist quinolinic acid and 3-hydroxykynurenine thereby enhancing oxidative stress and contributes to neurodegeneration which characterise major depression particularly in late life.While antidepressants attenuate some of the endocrine and immune changes caused by inflammation, not all therapeutically effective antidepressants do so. This suggests that drugs which specifically target the immune, endocrine and neurotransmitter systems may be more effective antidepressants.The preliminary clinical evidence that some non-steroidal anti-inflammatory drugs, such as the cyclooxygenase 2 inhibitor celecoxib, can enhance the response to standard antidepressant treatment is therefore considered and a critical assessment made of the possible limitations of such an approach to novel antidepressant development.

Entities:  

Keywords:  anti-inflammatory drugs; antidepressants; cytokines; inflammation; neurotoxins; prostaglandins

Mesh:

Substances:

Year:  2017        PMID: 28112061     DOI: 10.1017/neu.2016.69

Source DB:  PubMed          Journal:  Acta Neuropsychiatr        ISSN: 0924-2708            Impact factor:   3.403


  93 in total

1.  Longitudinal association of inflammation with depressive symptoms: A 7-year cross-lagged twin difference study.

Authors:  Minxuan Huang; Shaoyong Su; Jack Goldberg; Andrew H Miller; Oleksiy M Levantsevych; Lucy Shallenberger; Pratik Pimple; Bradley Pearce; J Douglas Bremner; Viola Vaccarino
Journal:  Brain Behav Immun       Date:  2018-10-27       Impact factor: 7.217

Review 2.  The role of microglia in chronic pain and depression: innocent bystander or culprit?

Authors:  Nan Yin; Enshi Yan; Wenbin Duan; Changyuan Mao; Qin Fei; Chun Yang; Yimin Hu; Xiaolin Xu
Journal:  Psychopharmacology (Berl)       Date:  2021-02-05       Impact factor: 4.530

Review 3.  Imaging and depression in multiple sclerosis: a historical perspective.

Authors:  Fabio Giuseppe Masuccio; Giulia Gamberini; Massimiliano Calabrese; Claudio Solaro
Journal:  Neurol Sci       Date:  2021-01-07       Impact factor: 3.307

Review 4.  The role of the gut-brain axis in depression: endocrine, neural, and immune pathways.

Authors:  Anastasios P Makris; Minois Karianaki; Konstantinos I Tsamis; Stavroula A Paschou
Journal:  Hormones (Athens)       Date:  2020-08-21       Impact factor: 2.885

5.  Longitudinal research on the bidirectional association between depression and arthritis.

Authors:  Chaofu Ke; Yanan Qiao; Siyuan Liu; Yuqi Rui; Ying Wu
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2020-11-22       Impact factor: 4.328

6.  Effects of Gender-Specific Differences, Inflammatory Response, and Genetic Variation on the Associations Among Depressive Symptoms and the Risk of Major Adverse Coronary Events in Patients With Acute Coronary Syndrome.

Authors:  Jennifer Sanner; Megan L Grove; Erica Yu; F Gerard Moeller; Stanley G Cron; Eric Boerwinkle; Alanna C Morrison; Lorraine Frazier
Journal:  Biol Res Nurs       Date:  2018-01-03       Impact factor: 2.522

Review 7.  Molecular Mechanisms Underlying the Anti-depressant Effects of Resveratrol: a Review.

Authors:  Marcos Roberto de Oliveira; Aline Lukasievicz Chenet; Adriane Ribeiro Duarte; Giselli Scaini; João Quevedo
Journal:  Mol Neurobiol       Date:  2017-07-10       Impact factor: 5.590

Review 8.  Major Depressive Disorder in Older Patients as an Inflammatory Disorder: Implications for the Pharmacological Management of Geriatric Depression.

Authors:  Malcolm P Forbes; Adrienne O'Neil; Melissa Lane; Bruno Agustini; Nick Myles; Michael Berk
Journal:  Drugs Aging       Date:  2021-04-29       Impact factor: 3.923

9.  Vaccination and Immunotherapy for Major Depression.

Authors:  Alper Evrensel; Barış Önen Ünsalver; Mehmet Emin Ceylan; Nevzat Tarhan
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

10.  Altered B Cell Homeostasis in Patients with Major Depressive Disorder and Normalization of CD5 Surface Expression on Regulatory B Cells in Treatment Responders.

Authors:  Diana Ahmetspahic; Kathrin Schwarte; Oliver Ambrée; Christian Bürger; Vladislava Falcone; Katharina Seiler; Mehrdad Rahbar Kooybaran; Laura Grosse; Fernand Roos; Julia Scheffer; Silke Jörgens; Katja Koelkebeck; Udo Dannlowski; Volker Arolt; Stefanie Scheu; Judith Alferink
Journal:  J Neuroimmune Pharmacol       Date:  2017-09-13       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.